Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY19 is not expected to be complete until September, 2020.

  1. Development of a protein drug for pancreatic cancer treatment

    SBC: ProDa BioTech L.L.C.            Topic: NCI

    Abstract Pancreatic cancers are devastating diseases with five year survival rate less thanCurrentlythere is no effective treatment for advanced diseaseOne major barrier to efficacy of anti tumor therapeutics is the dense desmoplastic stromal responseEvidence suggests that cancer associated pancreatic stellate cellsCAPaSCproduce the stromal collagenThe ECM laid down by CAPaSC is considered to be o ...

    STTR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health
  2. OC-Go: Facilitating fidelity and dissemination of evidence based treatment for childhood OCD via an interactive crowd-sourced patient-provider tool

    SBC: VIRTUALLY BETTER INC            Topic: 104

    The long term objective of this project is to leverage mobile technologies and crowdsourcing to create a new paradigm of evidence based treatment delivery and disseminationas current methods are often insufficientThe project seeks to refine and assess OC Goa HIPAA compliant web based clinician portal and patient side mobile application designed to increase patient adherence to evidence based treat ...

    STTR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health
  3. Detection and Staging of Liver Fibrosis by Precise MRI (pMRI)

    SBC: INLIGHTA BIOSCIENCES L.L.C.            Topic: NIAAA

    Abstract Chronic liver injury due to alcoholmetabolic dysfunctionviral hepatitisor autoimmune disease results in liver inflammation and fibrosisLiver fibrosis will progress to cirrhosis which is estimated to affectof the world s populationThe major clinical consequences of cirrhosis are liver failure and hepatocellular carcinomaHCCboth of which increase the risk of deathAlcoholic liver diseaseALDi ...

    STTR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health
  4. Proteasome inhibitor re-sensitizing molecules for treatment of refractory multiple myeloma

    SBC: Leukogene Therapeutics Inc.            Topic: 102

    Project Summary Abstract Multiple MyelomaMMis the second most common form of blood cancer and remains an incurable and deadly diseaseProteasome inhibitorPItherapy is a cornerstone in the treatment of MMbut resistance to this class of agent is an emerging challenge in the clinicNew therapeutic approaches that specifically target resistance are needed to maximize responses and ultimately produce cur ...

    STTR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government